WO2004032862A3 - Cyclodextrin-based materials, compositions and uses related thereto - Google Patents
Cyclodextrin-based materials, compositions and uses related thereto Download PDFInfo
- Publication number
- WO2004032862A3 WO2004032862A3 PCT/US2003/031991 US0331991W WO2004032862A3 WO 2004032862 A3 WO2004032862 A3 WO 2004032862A3 US 0331991 W US0331991 W US 0331991W WO 2004032862 A3 WO2004032862 A3 WO 2004032862A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- compositions
- based materials
- uses related
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003295344A AU2003295344B2 (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and uses related thereto |
JP2004543586A JP4602085B2 (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and related applications |
BR0315198-0A BR0315198A (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials and compositions and uses thereof |
CA002501132A CA2501132A1 (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and uses related thereto |
MXPA05003591A MXPA05003591A (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and uses related thereto. |
EP03786526A EP1549269A4 (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and uses related thereto |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41737302P | 2002-10-09 | 2002-10-09 | |
US60/417,373 | 2002-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004032862A2 WO2004032862A2 (en) | 2004-04-22 |
WO2004032862A3 true WO2004032862A3 (en) | 2004-07-01 |
Family
ID=32094010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/031991 WO2004032862A2 (en) | 2002-10-09 | 2003-10-08 | Cyclodextrin-based materials, compositions and uses related thereto |
Country Status (13)
Country | Link |
---|---|
US (3) | US8357377B2 (en) |
EP (1) | EP1549269A4 (en) |
JP (1) | JP4602085B2 (en) |
KR (1) | KR20050051686A (en) |
CN (1) | CN1717209A (en) |
AU (1) | AU2003295344B2 (en) |
BR (1) | BR0315198A (en) |
CA (1) | CA2501132A1 (en) |
MX (1) | MXPA05003591A (en) |
RU (1) | RU2005114007A (en) |
TW (1) | TW200423960A (en) |
WO (1) | WO2004032862A2 (en) |
ZA (1) | ZA200502754B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110179B2 (en) | 2002-09-06 | 2012-02-07 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050051686A (en) * | 2002-10-09 | 2005-06-01 | 인설트 테라페틱스, 인코퍼레이티드 | Cyclodextrin-based materials, compositions and uses related thereto |
SG129240A1 (en) * | 2003-01-23 | 2007-02-26 | Agency Science Tech & Res | Biodegradable copolymer and nucleic acid delivery system |
US7605120B2 (en) * | 2003-10-22 | 2009-10-20 | Amgen Inc. | Antagonists of the brandykinin B1 receptor |
KR20070007076A (en) | 2003-12-31 | 2007-01-12 | 사이덱스 인크 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER gamma;-CYCLODEXTRIN AND CORTICOSTEROID |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
ATE446581T1 (en) * | 2004-03-12 | 2009-11-15 | Trinity College Dublin | MAGNETORRESISTIVE MEDIUM |
CN1976708A (en) * | 2004-07-01 | 2007-06-06 | 荷兰癌症研究所 | Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyridimin-2-ylamino)phenyl]-benzamide |
ATE541928T1 (en) | 2005-03-31 | 2012-02-15 | Calando Pharmaceuticals Inc | RIBONUCLEOTIDE REDUCTASE SUBUNITY 2 INHIBITORS AND USES THEREOF |
JPWO2006115211A1 (en) * | 2005-04-25 | 2008-12-18 | 株式会社カネカ | Cyclodextrin-containing polyester polymer and process for producing the same |
WO2007009265A1 (en) * | 2005-07-22 | 2007-01-25 | The Governors Of The University Of Alberta Tec Edmonton | NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
JP2007211060A (en) * | 2006-02-07 | 2007-08-23 | Japan Advanced Institute Of Science & Technology Hokuriku | Supermolecule polymer and its synthetic method |
EP1988878A2 (en) * | 2006-02-15 | 2008-11-12 | Tika Läkemedel AB | Sterilization of corticosteroids with reduced mass loss |
KR100809046B1 (en) * | 2006-03-10 | 2008-03-03 | 가톨릭대학교 산학협력단 | Self assembled nanoparticle having pullulan and methods of using thereof |
US20080027212A1 (en) * | 2006-06-28 | 2008-01-31 | Skinner Keith K | Methods and compositions for improved uptake of biological molecules |
EP2121023A1 (en) * | 2006-12-22 | 2009-11-25 | 3M Innovative Properties Company | Controlled release composition and process |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
DK2130023T3 (en) | 2007-03-15 | 2015-06-08 | Ventana Med Syst Inc | Stabilized hematoxylin |
EP3766493B1 (en) | 2007-04-27 | 2023-08-23 | CyDex Pharmaceuticals, Inc. | Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin |
EP2170054A4 (en) * | 2007-06-28 | 2012-08-08 | Capsutech Ltd | Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers |
ITMI20071321A1 (en) * | 2007-07-04 | 2009-01-05 | Sea Marconi Technologies Di Va | CYCLODESTRINE-BASED NANOSPUGNE AS A VEHICLE FOR ANTITUMOR DRUGS |
EP2283133A2 (en) | 2008-04-04 | 2011-02-16 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
WO2010053487A1 (en) | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
WO2010088286A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
US20100197041A1 (en) * | 2009-01-30 | 2010-08-05 | Thomas Hermann | Nucleic acid binding assays |
CN102414116B (en) * | 2009-02-26 | 2015-01-21 | 加利福尼亚大学董事会 | A supramolecular approach for preparation of size controllable nanoparticles |
KR20190071006A (en) | 2009-05-13 | 2019-06-21 | 사이덱스 파마슈티칼스, 인크. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
CN106389307A (en) | 2009-05-29 | 2017-02-15 | 锡德克斯药物公司 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
WO2010141667A1 (en) * | 2009-06-03 | 2010-12-09 | Case Western Reserve University | Therapeutic agent delivery system and method |
CN102639142A (en) | 2009-09-16 | 2012-08-15 | 杜克大学 | Inhibition of endosomal toll-like receptor activation |
CN102711836B (en) | 2009-11-18 | 2017-05-10 | 尼克塔治疗公司 | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
CA2781669A1 (en) | 2009-11-23 | 2011-05-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US20110300150A1 (en) * | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
US20120213854A1 (en) * | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
CA2816319C (en) | 2010-11-01 | 2020-06-30 | Marshall Edwards, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
WO2013013245A2 (en) * | 2011-07-21 | 2013-01-24 | The Regents Of The University Of California | Catalytic delivery nanoubstrates (cdns) for highly efficient delivery of biomolecules |
CN103289075B (en) | 2012-02-22 | 2016-01-20 | 天津键凯科技有限公司 | The binding substances of polyoxyethylene glycol and naloxone and pharmaceutical composition thereof and application |
FR2989001B1 (en) * | 2012-04-06 | 2017-07-21 | Centre Nat Rech Scient | MICROPARTICLES AND NANOPARTICLES COMPRISING HYDROPHOBIC POLYSACCHARIDES AND ALPHA-CYCLODEXTRIN |
US9598503B2 (en) | 2012-04-18 | 2017-03-21 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
US9827321B2 (en) | 2012-08-14 | 2017-11-28 | The Trustees Of The University Of Pennsylvania | Stabilizing shear-thinning hydrogels |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
JP6445453B2 (en) * | 2012-11-28 | 2018-12-26 | ビクトリア リンク リミテッド | Dendritic core compound |
CN105358136B (en) * | 2013-02-15 | 2018-11-13 | 加利福尼亚大学董事会 | Supermolecule magnetic nano-particle |
US9321927B2 (en) | 2013-02-27 | 2016-04-26 | Crayola Llc | Enhanced washability inks and methods of making the same |
DE102013021060A1 (en) * | 2013-12-18 | 2015-06-18 | Rathor Ag | Process for the separation of monomers from isocyanate-containing prepolymers |
WO2016006413A1 (en) * | 2014-07-08 | 2016-01-14 | 国立大学法人大阪大学 | Self-restoring macromolecular material and production method for same |
CA2950694C (en) * | 2014-07-09 | 2019-04-02 | Halliburton Energy Services, Inc. | Treatment fluids for reducing subterranean formation damage |
CA2974123C (en) | 2015-02-02 | 2023-08-01 | Mei Pharma, Inc. | Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy |
BR112017027356B1 (en) | 2015-06-19 | 2024-01-02 | The University Of Queensland | COMPOSITION AND METHOD OF PREPARATION THEREOF, AGRICULTURAL PREPARATION FOR PROTECTING PLANTS AGAINST INSECTS, METHODS FOR DELIVERY OF DOUBLE-STANNED RNA TO AN INSECT AND FOR PROTECTING A CROP AGAINST AN INSECT, AND KIT |
CN105999289B (en) * | 2016-04-01 | 2018-11-20 | 南开大学 | A kind of super amphiphilic nano particle solution of binary and its preparation method and application |
CN106349396A (en) * | 2016-08-26 | 2017-01-25 | 湖南尔康制药股份有限公司 | Ultrasonic-sensitive crosslinked starch |
CN112011040B (en) * | 2020-07-20 | 2021-08-17 | 广州医科大学 | Multiple nano-delivery system and preparation method thereof |
WO2022029220A1 (en) | 2020-08-05 | 2022-02-10 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
EP4297790A1 (en) * | 2021-02-25 | 2024-01-03 | Noble Panacea Labs, Inc. | Assembly of organic supramolecular vessels for controlled drug release |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6033486A (en) * | 1996-07-09 | 2000-03-07 | Andros; Nicholas | Method for cleaning a surface by using a cationic sponge material |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1390479A (en) | 1973-09-05 | 1975-04-16 | I Orch Sinteza Akademii Nauk L | Pharmaceutical composition for treatment of parkinsonism |
DE2842862A1 (en) * | 1978-10-02 | 1980-04-10 | Boehringer Mannheim Gmbh | METHOD FOR DETERMINING ION, POLAR AND / OR LIPOPHILE SUBSTANCES IN LIQUIDS |
CH663951A5 (en) * | 1984-10-10 | 1988-01-29 | Nestle Sa | PROCESS FOR THE SELECTIVE ENRICHMENT OF POLYUNSATURATED FATTY ACIDS IN A MIXTURE CONTAINING ENRICHED FRACTION FATTY ACIDS AND COMPOSITIONS CONTAINING THE SAME. |
US4841081A (en) * | 1985-10-16 | 1989-06-20 | Osaka Soda Co., Ltd. | Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound |
GB2197720A (en) | 1986-11-20 | 1988-05-25 | Nat Res Dev | Immobilisation of polynucleotides |
EP0765936A1 (en) * | 1987-06-17 | 1997-04-02 | Institute For Child Health Research | Cloning of mite allergens |
US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
JP2614081B2 (en) * | 1988-05-27 | 1997-05-28 | 大塚化学株式会社 | Method for producing optically active β-lactam derivative |
US4887778A (en) * | 1988-06-01 | 1989-12-19 | Universal Instruments Corporation | Feeder drive assembly and replaceable section for tape supplying and cover peeling |
HU200913B (en) | 1988-07-28 | 1990-09-28 | Ciklodextrin Kutato Fejlesztoe | Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility |
US5098793A (en) * | 1988-09-29 | 1992-03-24 | Uop | Cyclodextrin films on solid substrates |
US5139687A (en) | 1990-05-09 | 1992-08-18 | The Proctor & Gamble Company | Non-destructive carriers for cyclodextrin complexes |
JPH0425505A (en) * | 1990-05-21 | 1992-01-29 | Toppan Printing Co Ltd | Cyclodextrain polymer and production of cyclodextrin membrane |
WO1992009637A1 (en) * | 1990-11-30 | 1992-06-11 | Toppan Printing Co., Ltd. | Process for producing cyclodextrin derivative and polymer containing cyclodextrin immobilized therein |
JP2976154B2 (en) * | 1991-11-27 | 1999-11-10 | コニカ株式会社 | Solid processing agents for silver halide photographic materials |
HU210922B (en) | 1993-05-24 | 1995-09-28 | Europharmaceuticals Sa | Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them |
US5880154A (en) * | 1994-02-01 | 1999-03-09 | The Board Of Regents Of The University Of Nebraska | Polymeric adamantane analogues |
HU218280B (en) * | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
US5691316A (en) * | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
JP3699141B2 (en) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | Biomolecular assembly of biodegradable pharmaceutical polymer having supramolecular structure and preparation method thereof |
US5728804A (en) * | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
DE19629494A1 (en) * | 1996-07-09 | 1998-01-15 | Schering Ag | Pseudopolyrotaxanes |
WO1998047536A1 (en) | 1997-04-23 | 1998-10-29 | University Of Otago | Controlled release of ophthalmic compositions |
JPH11100401A (en) * | 1997-07-30 | 1999-04-13 | Kikkoman Corp | Cyclic oligosaccharide and preventive or treating agent for retrovirus disease containing the same |
NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
IT1298732B1 (en) | 1998-03-13 | 2000-02-02 | Recordati Chem Pharm | ORAL PHARMACEUTICAL COMPOSITIONS ASSUMABLE WITHOUT LIQUIDS, CONTAINING INCLUSION COMPLEXES |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6509323B1 (en) * | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6261583B1 (en) * | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
EP1133318B1 (en) | 1998-12-04 | 2007-03-14 | California Institute of Technology | Supramolecular complexes containing therapeutic agents |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
US6740643B2 (en) * | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
WO2000075164A1 (en) | 1999-06-07 | 2000-12-14 | Mirus Corporation | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
EP1102784A4 (en) | 1999-06-07 | 2009-12-30 | Mirus Bio Corp | A compound containing a labile disulfide bond |
EP1233671A4 (en) | 1999-11-29 | 2005-11-02 | Mirus Corp | Compositions and methods for drug delivery using amphiphile binding molecules |
SK282717B6 (en) | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Preparation method of ultrahigh molecular hyaluronans |
AU2001279164A1 (en) * | 2000-08-01 | 2002-02-13 | Oregon Health And Science University | Mammalian dna binding membrane-associated protein-encoding gene and uses |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
BRPI0314042B8 (en) * | 2002-09-06 | 2021-05-25 | Calando Pharmaceuticals Inc | cyclodextrin-based polymers for the delivery of covalently linked therapeutic agents |
KR20050051686A (en) | 2002-10-09 | 2005-06-01 | 인설트 테라페틱스, 인코퍼레이티드 | Cyclodextrin-based materials, compositions and uses related thereto |
US20080176958A1 (en) * | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
-
2003
- 2003-10-08 KR KR1020057006045A patent/KR20050051686A/en not_active Application Discontinuation
- 2003-10-08 BR BR0315198-0A patent/BR0315198A/en not_active IP Right Cessation
- 2003-10-08 CA CA002501132A patent/CA2501132A1/en not_active Abandoned
- 2003-10-08 MX MXPA05003591A patent/MXPA05003591A/en not_active Application Discontinuation
- 2003-10-08 CN CNA2003801045673A patent/CN1717209A/en active Pending
- 2003-10-08 EP EP03786526A patent/EP1549269A4/en not_active Withdrawn
- 2003-10-08 AU AU2003295344A patent/AU2003295344B2/en not_active Ceased
- 2003-10-08 JP JP2004543586A patent/JP4602085B2/en not_active Expired - Fee Related
- 2003-10-08 US US10/681,745 patent/US8357377B2/en not_active Expired - Fee Related
- 2003-10-08 RU RU2005114007/04A patent/RU2005114007A/en not_active Application Discontinuation
- 2003-10-08 WO PCT/US2003/031991 patent/WO2004032862A2/en active Application Filing
- 2003-10-09 TW TW092128118A patent/TW200423960A/en unknown
-
2005
- 2005-04-05 ZA ZA200502754A patent/ZA200502754B/en unknown
-
2012
- 2012-12-06 US US13/707,217 patent/US20130315980A1/en not_active Abandoned
-
2013
- 2013-08-15 US US13/968,112 patent/US20140199370A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6033486A (en) * | 1996-07-09 | 2000-03-07 | Andros; Nicholas | Method for cleaning a surface by using a cationic sponge material |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110179B2 (en) | 2002-09-06 | 2012-02-07 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
Also Published As
Publication number | Publication date |
---|---|
ZA200502754B (en) | 2006-09-27 |
US20040109888A1 (en) | 2004-06-10 |
US8357377B2 (en) | 2013-01-22 |
EP1549269A4 (en) | 2010-10-06 |
AU2003295344A1 (en) | 2004-05-04 |
BR0315198A (en) | 2005-08-30 |
RU2005114007A (en) | 2005-10-10 |
US20140199370A1 (en) | 2014-07-17 |
US20130315980A1 (en) | 2013-11-28 |
AU2003295344B2 (en) | 2008-01-31 |
MXPA05003591A (en) | 2005-09-30 |
EP1549269A2 (en) | 2005-07-06 |
KR20050051686A (en) | 2005-06-01 |
JP4602085B2 (en) | 2010-12-22 |
TW200423960A (en) | 2004-11-16 |
WO2004032862A2 (en) | 2004-04-22 |
CA2501132A1 (en) | 2004-04-22 |
JP2006513992A (en) | 2006-04-27 |
CN1717209A (en) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004032862A3 (en) | Cyclodextrin-based materials, compositions and uses related thereto | |
WO2005112886A3 (en) | Methods and articles for the delivery of therapeutic agents | |
AU3468900A (en) | Cyclodextrin polymers for use as drug carriers | |
WO2004093795A3 (en) | Compositions for delivery of drug combinations | |
WO2004039428A3 (en) | Transdermal delivery system for dried particulate or lyophilized medications | |
WO2006039336A3 (en) | Conveniently implantable sustained release drug compositions | |
WO2004026231A3 (en) | Formulation for lipophilic agents | |
ATE355829T1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE INGREDIENT AND THE PRODUCTION THEREOF | |
WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
WO2004052336A3 (en) | High viscosity liquid controlled delivery system and medical or surgical device | |
WO2001062737A3 (en) | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | |
WO2003028657A3 (en) | Compositions for oral gene therapy and methods of using same | |
WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
BR9914360A (en) | N-aralkylaminotetralins as ligands for neuropeptide receptor yy5 | |
WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
WO2008061014A3 (en) | Self-assembling peptide amphiphiles for tissue engineering | |
BRPI0416613A (en) | composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | |
IL163552A (en) | Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same | |
CA2303498A1 (en) | Dioxocyclopentyl hydroxamic acids | |
FR2884252B1 (en) | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY | |
WO2003028696A8 (en) | Compositions for delivery of drug combinations | |
WO2004104021A3 (en) | Controlled release of active agents utilizing repeat sequence protein polymers | |
DE50311778D1 (en) | MIXING SYSTEM FOR THE SOLUBILITY MANAGEMENT OF PHARMACEUTICAL AGENTS IN POLYMERMATRICES | |
WO2007017331A3 (en) | Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin | |
WO2006021001A3 (en) | Amphiphilic polynorbornene derivatives and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 167583 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003786526 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003295344 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2501132 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/02754 Country of ref document: ZA Ref document number: 200502754 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004543586 Country of ref document: JP Ref document number: 1020057006045 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005114007 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A45673 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006045 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786526 Country of ref document: EP |